Navigation Links
FDA Accepts Sucampo's sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
Date:9/17/2007

f The Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the words "project," "believe," "anticipate," "plan," "expect," "estimate," "intend," "should," "would," "could," "will," "may" or other similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the results of clinical trials with respect to Sucampo Pharmaceuticals' products under development; the timing and success of submission, acceptance, review and approval of regulatory filings; Sucampo Pharmaceuticals' dependence on the commercial success of AMITIZA; Sucampo Pharmaceuticals' ability to obtain additional funding required to conduct its discovery, development and commercialization programs; Sucampo Pharmaceuticals' dependence on its co- marketing alliance with Takeda Pharmaceutical Company Limited; and Sucampo Pharmaceuticals' ability to obtain, maintain and enforce patent and other intellectual property protection for its discoveries. These and other risks are described in greater detail in the "Risk Factors" section of the Sucampo Pharmaceuticals' quarterly report on Form 10-Q filed with the Securities and Exchange Commission on August 22, 2007. Any forward-looking statements in this press release represent Sucampo Pharmaceuticals' views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Sucampo Pharmaceuticals anticipates that subsequent events and developments will cause its views to change. However, while Sucampo Pharmaceuticals may elect to update these forward-looking statements publicly at some point in the future, it specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise.

Contact:

Scott Solomon

Vice President

Sharon Merrill Associates, Inc.

Tel: 617-542-5300


'/>"/>
SOURCE Sucampo Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. UWM accepts resignation of research dean
2. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
3. Improve Recovery and Reproducibility with Pre-Treatment of Analytical TSK-GEL G3000SWXL Size Exclusion Columns
4. Quintessence cancer treatment chosen for clinical studies
5. ZyStor to exhibit cell disorder treatments
6. Radiology advance points way to non-invasive brain-cancer treatment
7. Animal testing: Beyond the protests, instances of mistreatment are rare
8. TomoTherapy leads the industry in CT image-guided treatments
9. Medical College getting $18.1 million to study radiation damage treatments
10. `Single-sales factor extends tax treatment to tech, service firms
11. Research on fruit flies opens up possibilities for human treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Texas (PRWEB) March 05, 2015 ... of acute and chronic orthopedic conditions such as ... knee, tennis elbow, and joint pain due to ... be administered during orthopedic surgeries to promote better ... scientific advances in nearly pain-free bone marrow harvesting ...
(Date:3/4/2015)... March 4, 2015 The UPMC Center for ... Fellows in the Emerging Leaders in Biosecurity Initiative (ELBI). ... in the field of biosecurity, UPMC has selected 28 ... wide array of backgrounds, including biological science, medicine, policy, ... "With the vision and support of the ...
(Date:3/4/2015)... Mar. 04, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "Biomarkers - ... This report follows the broad ... can be objectively measured and evaluated as an ... well as pharmacological responses to a therapeutic intervention. ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 PRC ... in the San Francisco Bay Area, will exhibit and ... Israel Conference 2015 on March 25th and 26th ... to build relationships with Israeli life science companies seeking ... trials. The company’s services span all phases of human ...
Breaking Biology Technology:Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 2PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 3PRC Clinical to Present at Inaugural Outsourcing in Clinical Trials Israel Conference 2015 on March 25 and 26th in Tel Aviv 4
... of Healthcare Products to ... and Bleeding Disorders, OTTAWA, April 3, 2008 ... Blood Services, and Hema-Quebec, have each awarded,the company ... P (Antihemophilic factor / von Willebrand Factor,Complex [Human], ...
... the Anniversary by Ringing The Closing Bell(R) at ... the ... Edwards,Lifesciences Corporation (NYSE: EW ), a world leader in ... of partnering with clinicians to develop life-saving,innovations. To celebrate its five ...
... Anadys,Pharmaceuticals, Inc. (Nasdaq: ANDS ) announced today ... Conference on Wednesday, April 9, 2008,at 3:00 p.m. EDT ... the St.,Regis Hotel in New York City., Steve ... Inc., will present an overview of Anadys and an ...
Cached Biology Technology:CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 2CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 3CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 4CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 5CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 6CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 7CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies 8Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations 2Edwards Lifesciences Celebrates 50 Years of Life-Saving Innovations 3Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference 2
(Date:2/23/2015)... , Feb. 23, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... filed provisional patent 62114357 for DISTRIBUTED VOICE ... patent, NXT-ID introduces a new groundbreaking payment method. Payment ... payment account may only be accessed if both the ...
(Date:2/12/2015)... , Feb. 12, 2015   MedNet ... specializing in clinical study management systems, has recently ... , further distinguishing iMedNet ... Research Organizations (CROs) and healthcare consultants.  Building on ... prospective customer referrals and numerous co-marketing opportunities), MedNet,s ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
Breaking Biology News(10 mins):NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... University College of Dentistry (NYUCD) research team has found the ... sapiens out of Africa to Asia. , The ... comprehensive care at NYUCD, discovered that Streptoccocus mutans, a bacterium ... hosts in a clear line that can be traced back ...
... is highly effective in preventing death from lung cancer ... disease by up to 70%. In addition, new research ... increases the risk of dying from lung cancer in ... the continuing popularity of cigarette smoking across large parts ...
... care unit (ICU) already are seriously ill, so the last ... that as many as 25 percent of all patients admitted ... can be fatal. , Ventilator-associated pneumonia is a major cause ... this infection can add $40,000 to costs and double the ...
Cached Biology News:'Ancestral eve' was mother of all tooth decay 2Quitting smoking reduces risk of lung cancer mortality by 70 percent 2Bacteria from patient's dental plaque causes ventilator-associated pneumonia 2
Mouse monoclonal [DJR3] to DcR1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
GBL Antibody...
Human acetylcholine receptor (AChR)-alpha. Exhibits homogenous, high affinity,binding to the receptor. Binds weakly to a64-78. Inhibits binding of many,myasthenia gravis sera to human AChR....
... [SPM278] to 67kD Laminin Receptor, prediluted ... live cells (Human). Reactivity / Specificity ... in other species. Background Information ... basement membrane, displays multiple biological activities which ...
Biology Products: